For many patients with basal cell carcinomas or squamous cell carcinoma, radiation therapy can yield better functional or cosmetic outcomes than surgical intervention and radiation therapy may be the preferred option. For other patients with medical comorbidities or...
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Radiant Aura at the AOCD 2024 meeting, in Scottsdale, AZ. Radiant Aura is a new low-dose, X-ray based, dual modality radiation therapy for treating non-melanoma skin cancers (NMSC) and keloid scarring. Visit Xstrahl at AOCD 2024, booth # 22 at the Westin Kierland from April 11-14, 2024.
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Radiant Aura at the Maui Derm Hawaii 2024 meeting, January 22-26, 2024. Radiant Aura is a new low-dose, X-ray based, dual modality radiation therapy for treating non-melanoma skin cancers (NMSC) and keloid scarring.
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Radiant Aura at the Maui Derm Hawaii 2024 meeting, January 22-26, 2024. Radiant Aura is a new low-dose, X-ray based, dual modality radiation therapy for treating non-melanoma skin cancers (NMSC) and keloid scarring.
Reaching Out to Improve Access to Radiation Therapy Treatment: Xstrahl attends regional conferences to meet with clinicians and discuss radiation therapy
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Radiant Aura, a new low-dose, X-ray based, dual modality radiation therapy for treating non-melanoma skin cancers (NMSC) and keloid scarring at the American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting in San Diego, CA, October 1-3, 2023, booth #2216.
The Dermatology Insider 2023 is Xstrahl’s magazine for dermatologists. This issue of the Dermatology Insider includes patient stories about having SRT treatment for their skin cancer. In addition, hear from a dermatologist as he describes his experience using radiation therapy to treat non-melanoma skin cancer (NMSC). See two case history reports of radiation therapy treatment for skin cancer using SRT and eBt, detailing the number of treatments, dose per treatment, reasons for radiation therapy, as well as before and after images of the results. Xstrahl introduces Radiant Aura, which recently received US Food & Drug Administration (FDA) 510(k) Clearance. We share more about using Radiant Aura and answer the most commonly asked questions in our FAQ section.
Radiant™ Aura Receives U.S. Food and Drug Administration (FDA) 510(k) Clearance
Expands office-based treatment options for millions of non-melanoma skin cancer (NMSC) patients
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, announced its Radiant™ Aura treatment solution has received U.S. Food and Drug Administration (FDA) 510(k) clearance. With advanced features for expanded clinical use, simplified patient positioning, and additional patient comfort, Radiant Aura brings radiation therapy to NMSC patients in any dermatology office.
In this case, Xstrahl 100 was used to treat a keloid scar on an earlobe that developed from an ear piercing.
Contact Us